Lupus Just Humbled Another TYK2 Drug

The Subgroup Silver Lining (If You Squint)

Alumis didn't wave a white flag, though. The company pointed to a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high). In plain English: these are patients whose lupus is driven heavily by a specific arm of the immune system, the type I interferon pathway. In that subgroup, envudeucitinib showed "robust responses" across BICLA, CLASI-50, SRI-4, and LLDAS.

The problem? The trial apparently enrolled a higher-than-expected proportion of IFNGS-low patients, which may have diluted the overall results and inflated the placebo response rate. Alumis now argues this explains the miss, and that the "right" patient population responded well.

This is a familiar playbook in biotech. When a trial fails overall, companies point to a subgroup that worked and pitch it as the real story. Sometimes they're right (Keytruda's PD-L1 biomarker strategy turned out to be revolutionary). Sometimes it's just the scientific equivalent of "the referee blew the call."

Can Alumis Really Talk Its Way Into Phase 3?

Alumis leadership says they see a "clear path forward" and plan to discuss Phase 3 development with regulators. The likely strategy: design the next trial to restrict enrollment to IFNGS-high patients, or at least cap the proportion of IFNGS-low patients. The company has suggested the overall SLE development timeline may not even change much.

That's an optimistic read. Regulators will want to see whether the subgroup analysis was truly prespecified and robust enough to anchor a pivotal program. Running a biomarker-enriched Phase 3 is doable, but it narrows the eventual addressable market. And investors will need to fund it; that's a harder sell when your stock just lost 58% of its value.

Meanwhile, the psoriasis franchise is the near-term lifeline. Alumis expects to submit its NDA (new drug application) for plaque psoriasis in Q4 2026, based on positive Phase 3 results from its ONWARD program. If that goes well, it keeps the lights on while the lupus strategy gets retooled.

A Bigger Question for the TYK2 Class

Zoom out, and this trial adds to a growing pattern. TYK2 inhibition has been a star in psoriasis but has struggled to prove itself in other autoimmune diseases. Bristol-Myers Squibb's deucravacitinib, the first approved TYK2 inhibitor, has shown some early signals in lupus, but nothing that's made it to Phase 3 confirmation yet. Other autoimmune indications like psoriatic arthritis and inflammatory bowel disease remain works in progress for the class.

The original promise of TYK2 inhibitors was that they'd deliver the potency of JAK inhibitors (drugs like tofacitinib and upadacitinib) with fewer safety concerns, because TYK2 is a more selective target. That safety profile still looks solid. But selectivity cuts both ways: if you're only blocking one switch, you might not be flipping enough of the right ones to control a complex disease like lupus.

Lupus Remains One of Biotech's Toughest Puzzles

The lupus treatment landscape is busy but far from solved. Beyond the standard cocktail of immunosuppressants, only a handful of targeted therapies have reached approval: belimumab, anifrolumab, and voclosporin for lupus nephritis. One recent pipeline report counted over 140 therapies from 120+ companies in clinical trials for the disease.

Even CAR-T cell therapy (yes, the cancer approach) is being tested in the most refractory lupus patients. There's no shortage of ambition; there's a shortage of drugs that actually work in a broad lupus population.

That's the core challenge Alumis just ran into. Lupus is heterogeneous by nature, meaning different patients have different underlying biology driving their disease. A single mechanism may only help a slice of them. The IFNGS-high subgroup strategy might be scientifically sound, but it's also an admission that envudeucitinib probably can't help everyone with lupus.

The Bottom Line

Alumis still has a viable psoriasis franchise and a plausible (if narrower) path forward in lupus. But the stock reaction tells you everything about how the market weighs those two things. Investors bought into Alumis for the lupus upside; the psoriasis program was supposed to be the foundation, not the whole house.

For the broader TYK2 class, the LUMUS miss is another data point suggesting that psoriasis might be the sweet spot rather than the starting line. Blocking TYK2 works beautifully for skin. Whether it can conquer the complex, multi-organ chaos of lupus is still very much an open question.

Arsenal Bio Just Torched Its Own Playbook. Here's Why.

Arsenal Biosciences just fired 99 employees, killed its clinical programs, and bet everything on a technology that barely exists in the clinic. When a company backed by $630 million torches its own playbook, it tells you something important about where cell therapy is headed.